Development of Antibody-Based Therapeutics: Translational Considerations

0 avg rating
( 0 ratings by Goodreads )
 
9781441959539: Development of Antibody-Based Therapeutics: Translational Considerations

Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the ‘unit dose’ and ‘unit effect’ with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in "relevant" animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen distribution, expression profile, kinetic properties, target pharmacology, antigen isoforms and pharmacological redundancy in health and disease, as well as antibody design criteria, such as antibody isotype, affinity, PK/PD and safety is a critical necessity for the design of effective translational strategies. Additionally, these factors will further offer critical differentiating characteristics for next-generation antibodies, and novel technologies prove instrumental in generation of biosuperior antibody candidates for market entry. This book will examine many important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics.

"synopsis" may belong to another edition of this title.

From the Back Cover:

Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the ‘unit dose’ and ‘unit effect’ with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates.  Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in “relevant” animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies.  This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics.

About the Author:

Mohammad Tabrizi, Ph.D., Vice President, Preclinical Development, AnaptysBio Inc. Mohammad Tabrizi is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies. He is currently the Vice President of Preclinical Development at AnaptysBio, Inc., a privately held biotechnology company in San Diego CA, USA, the leader in Somatic HyperMutation (SHM) for development of therapeutic antibodies where he advances the preclinical development efforts.

Gadi Gazit Bornstein, Ph.D., Principal Scientist, AstraZeneca R&D Boston Dr. Bornstein has experience in research and development with an emphasis in development of therapeutic monoclonal antibodies in oncology. Dr. Bornstein is a Principal Scientist at AstraZeneca, where he currently leads several antibody programs within the Preclinical oncology portfolio. He received his B.S. in biochemistry at the University of California, Davis and his doctoral degree in biochemistry at the Keck School of Medicine of the University of Southern California. Dr. Bornstein completed his postdoctoral training at Stanford University School of Medicine in the Division of Immunology and Rheumatology. Following his postdoctoral training, Dr. Bornstein joined Amgen Fremont, Inc. (formerly Abgenix, Inc.) as a Staff Scientist in the Preclinical Oncology Department. During his tenure at Abgenix, he was a project team leader and lead biologist for multiple antibody programs.

Scott L. Klakamp, Ph.D., Research Fellow, Biophysical Chemistry and Research Informatics, Takeda San Francisco Scott Klakamp is one of the leading scientists in utilizing Biacore®, KinExA®, and FACS techniques to measure the binding kinetics and equilibrium constants of human monoclonal antibody/antigen complexes. He has extensive experience in research and development involving the biophysical and analytical characterization of biologics and monoclonal antibodies (mAb). He has also contributed significantly to the clinical immunology field by applying highly rigorous analytical detection concepts, previously unknown to the discipline, to immunogenicity studies of therapeutic mAbs. Currently, he is a Research Fellow at Takeda San Francisco, the therapeutic monoclonal antibody discovery engine for Takeda Pharmaceutical Company, and leads the Biophysical Chemistry and Research Informatics Groups.

"About this title" may belong to another edition of this title.

Top Search Results from the AbeBooks Marketplace

1.

Published by Springer-Verlag New York Inc., United States (2012)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Hardcover Quantity Available: 1
Seller:
The Book Depository
(London, United Kingdom)
Rating
[?]

Book Description Springer-Verlag New York Inc., United States, 2012. Hardback. Book Condition: New. 2012. Language: English . Brand New Book. Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the `unit dose and `unit effect with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in relevant animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen distribution, expression profile, kinetic properties, target pharmacology, antigen isoforms and pharmacological redundancy in health and disease, as well as antibody design criteria, such as antibody isotype, affinity, PK/PD and safety is a critical necessity for the design of effective translational strategies. Additionally, these factors will further offer critical differentiating characteristics for next-generation antibodies, and novel technologies prove instrumental in generation of biosuperior antibody candidates for market entry. This book will examine many important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Bookseller Inventory # LIB9781441959539

More Information About This Seller | Ask Bookseller a Question

Buy New
145.44
Convert Currency

Add to Basket

Shipping: FREE
Within United Kingdom
Destination, Rates & Speeds

2.

Published by Springer (2012)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Hardcover Quantity Available: 1
Print on Demand
Seller:
Revaluation Books
(Exeter, United Kingdom)
Rating
[?]

Book Description Springer, 2012. Hardcover. Book Condition: Brand New. 1st edition. 425 pages. 9.50x6.25x1.25 inches. This item is printed on demand. Bookseller Inventory # zk144195953X

More Information About This Seller | Ask Bookseller a Question

Buy New
142.70
Convert Currency

Add to Basket

Shipping: 2.75
Within United Kingdom
Destination, Rates & Speeds

3.

Published by Springer-Verlag New York Inc., United States (2012)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Hardcover Quantity Available: 1
Seller:
The Book Depository US
(London, United Kingdom)
Rating
[?]

Book Description Springer-Verlag New York Inc., United States, 2012. Hardback. Book Condition: New. 2012. Language: English . Brand New Book. Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the `unit dose and `unit effect with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in relevant animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen distribution, expression profile, kinetic properties, target pharmacology, antigen isoforms and pharmacological redundancy in health and disease, as well as antibody design criteria, such as antibody isotype, affinity, PK/PD and safety is a critical necessity for the design of effective translational strategies. Additionally, these factors will further offer critical differentiating characteristics for next-generation antibodies, and novel technologies prove instrumental in generation of biosuperior antibody candidates for market entry. This book will examine many important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Bookseller Inventory # LIB9781441959539

More Information About This Seller | Ask Bookseller a Question

Buy New
157.49
Convert Currency

Add to Basket

Shipping: FREE
Within United Kingdom
Destination, Rates & Speeds

4.

Mohammad A. Tabrizi, Gadi Gazit Bornstein, Scott L. Klakamp
Published by Springer 2012-04-24 (2012)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Quantity Available: 3
Seller:
Chiron Media
(Wallingford, United Kingdom)
Rating
[?]

Book Description Springer 2012-04-24, 2012. Book Condition: New. Brand new book, sourced directly from publisher. Dispatch time is 24-48 hours from our warehouse. Book will be sent in robust, secure packaging to ensure it reaches you securely. Bookseller Inventory # NU-LBR-01060624

More Information About This Seller | Ask Bookseller a Question

Buy New
158.25
Convert Currency

Add to Basket

Shipping: 2.49
Within United Kingdom
Destination, Rates & Speeds

5.

Mohammad A. Tabrizi (editor), Gadi G. Bornstein (editor), Scott L. Klakamp (editor)
Published by Springer New York 2012-04-24, New York |London (2012)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Hardcover Quantity Available: 10
Seller:
Blackwell's
(Oxford, OX, United Kingdom)
Rating
[?]

Book Description Springer New York 2012-04-24, New York |London, 2012. hardback. Book Condition: New. Bookseller Inventory # 9781441959539

More Information About This Seller | Ask Bookseller a Question

Buy New
163.99
Convert Currency

Add to Basket

Shipping: FREE
Within United Kingdom
Destination, Rates & Speeds

6.

MOHAMMAD A. TABRIZI
Published by Springer (2012)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Hardcover Quantity Available: 1
Seller:
Herb Tandree Philosophy Books
(Stroud, GLOS, United Kingdom)
Rating
[?]

Book Description Springer, 2012. Hardback. Book Condition: NEW. 9781441959539 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. For all enquiries, please contact Herb Tandree Philosophy Books directly - customer service is our primary goal. Bookseller Inventory # HTANDREE0297863

More Information About This Seller | Ask Bookseller a Question

Buy New
165
Convert Currency

Add to Basket

Shipping: 3.75
Within United Kingdom
Destination, Rates & Speeds

7.

Tabrizi, Mohammad A.
Published by Springer (2016)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Paperback Quantity Available: 1
Print on Demand
Seller:
Ria Christie Collections
(Uxbridge, United Kingdom)
Rating
[?]

Book Description Springer, 2016. Paperback. Book Condition: New. PRINT ON DEMAND Book; New; Publication Year 2016; Not Signed; Fast Shipping from the UK. No. book. Bookseller Inventory # ria9781441959539_lsuk

More Information About This Seller | Ask Bookseller a Question

Buy New
172.23
Convert Currency

Add to Basket

Shipping: FREE
Within United Kingdom
Destination, Rates & Speeds

8.

Mohammad A. Tabrizi, Gadi Gazit Bornstein, Scott L. Klakamp
Published by Springer 2012-04-24 (2012)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Quantity Available: 5
Seller:
Chiron Media
(Wallingford, United Kingdom)
Rating
[?]

Book Description Springer 2012-04-24, 2012. Book Condition: New. Brand new book, sourced directly from publisher. Dispatched within 2 working days from our warehouse. Book will be sent in robust, secure packaging to ensure it reaches you securely. Bookseller Inventory # NU-ING-27538699

More Information About This Seller | Ask Bookseller a Question

Buy New
186.41
Convert Currency

Add to Basket

Shipping: 2.49
Within United Kingdom
Destination, Rates & Speeds

9.

Tabrizi, Mohammad A. [Editor]; Bornstein, Gadi G. [Editor]; Klakamp, Scott L. [Editor];
Published by Springer (2012)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Hardcover Quantity Available: 10
Seller:
Ergodebooks
(RICHMOND, TX, U.S.A.)
Rating
[?]

Book Description Springer, 2012. Hardcover. Book Condition: New. Bookseller Inventory # INGM9781441959539

More Information About This Seller | Ask Bookseller a Question

Buy New
182.22
Convert Currency

Add to Basket

Shipping: 6.75
From U.S.A. to United Kingdom
Destination, Rates & Speeds

10.

Mohammad A. Tabrizi
Published by Springer-Verlag Gmbh Apr 2012 (2012)
ISBN 10: 144195953X ISBN 13: 9781441959539
New Quantity Available: 1
Seller:
Rheinberg-Buch
(Bergisch Gladbach, Germany)
Rating
[?]

Book Description Springer-Verlag Gmbh Apr 2012, 2012. Buch. Book Condition: Neu. Neuware - Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in 'relevant' animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen distribution, expression profile, kinetic properties, target pharmacology, antigen isoforms and pharmacological redundancy in health and disease, as well as antibody design criteria, such as antibody isotype, affinity, PK/PD and safety is a critical necessity for the design of effective translational strategies. Additionally, these factors will further offer critical differentiating characteristics for next-generation antibodies, and novel technologies prove instrumental in generation of biosuperior antibody candidates for market entry. This book will examine many important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. 425 pp. Englisch. Bookseller Inventory # 9781441959539

More Information About This Seller | Ask Bookseller a Question

Buy New
181.68
Convert Currency

Add to Basket

Shipping: 8.73
From Germany to United Kingdom
Destination, Rates & Speeds

There are more copies of this book

View all search results for this book